Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPS-derived corneal cell therapy
- Development stage
- Unknown
- Lead developer
- Cellusion
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intracameral Injection, Surgical Implantation
01
Overview
iPS-derived corneal cell therapy is a regenerative medicine product consisting of a sheet of corneal epithelial cells derived from allogeneic induced pluripotent stem cells (iPSCs). Developed by Osaka University in collaboration with Sumitomo Pharma, the therapy is designed to treat corneal epithelial stem cell deficiency (LSCD), a condition where the loss of limbal stem cells leads to corneal opacity, edema, and vision loss. The treatment involves the surgical transplantation of a lab-grown cell sheet onto the patient's ocular surface to restore a functional corneal epithelium. This approach aims to provide a stable and transparent corneal surface without the need for autologous tissue or long-term immunosuppression typically required for allogeneic tissue transplants.
- Other names
- iPS-derived corneal epithelial cell sheetallogeneic iPS-derived corneal epithelial cell sheetiPS-derived corneal cell therapy
Beyond the preview
Go deeper on iPS-derived corneal cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPS-derived corneal cell therapy.